Citalopram hydrobromide

Material Safety Data Sheet

Hazard Alert Code Key: EXTREME | HIGH | MODERATE | LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Citalopram hydrobromide

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY
ChemWatch
Within the US & Canada: 877–715–9305
Outside the US & Canada: +800 2436 2255
(1–800-CHEMCALL) or call +613 9573 3112

SYNONYMS
C20-H21-F-N2-O.HBr, "1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1, 3-dihydro-5-", "isobenzofuran-carbonitrile hydrobromide", 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-, "5-phthalancarbonitrile hydrobromide", "nitalapram hydrobromide", Lu-10-171, "bicyclic antidepressant"

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th></th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity:</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Body Contact:</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Reactivity:</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Chronic:</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

CANADIAN WHMIS SYMBOLS

1 of 8
EMERGENCY OVERVIEW

RISK
Contact with acids liberates very toxic gas. Possible risk of harm to the unborn child. Very toxic to aquatic organisms.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be damaging to the health of the individual.
- Nitrile poisoning exhibits similar symptoms to poisoning due to hydrogen cyanide.
- The substances irritate the eyes and skin, and are absorbed quickly and completely through the skin.
- Aromatic nitriles, unlike aliphatic nitriles, do not appear to liberate cyanide within the body.
- Patients of any age with Major Depressive Disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behaviour (suicidality), whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.
- Patients should be closely monitored, especially at the beginning of therapy or when the dose is changed, until such improvement occurs.
- Serotonin syndrome (serious changes to how the brain, muscles and digestive system works due to high levels of serotonin in the body) may occur in therapy.
- Signs and symptoms of serotonin syndrome include: restlessness, fast heart beat, fast changes in blood pressure, diarrhoea and vomiting, nausea, hallucinations, increased body temperature, coma, loss of coordination, overactive reflexes. General side effects of serotonin reuptake inhibitors (SSRIs) are mostly present during the first 1-4 weeks while the body adapts to the drug (with the exception of sexual side effects, which tend to occur later in treatment).
- Bromide poisoning causes intense vomiting so the dose is often removed.
- Effects include drowsiness, irritability, inco-ordination, vertigo, confusion, mania, hallucinations and coma.

EYE
- Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn).
- Slight abrasive damage may also result.

SKIN
- Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.
- There is some evidence to suggest that this material can cause inflammation of the skin on contact in some persons.
- This material is a photosensitizer.
- Certain individuals working with this substance may show allergic reaction of the skin under sunlight.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects.
- Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
- The material is not thought to produce respiratory irritation (as classified using animal models).
- Nevertheless inhalation of dusts, or fume, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.
- Inhalation of dusts, generated by the material during the course of normal handling, may be damaging to the health of the individual.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS
- Results in experiments suggest that this material may cause disorders in the development of the embryo or fetus, even when no signs of poisoning show in the mother.
- Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.
- Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung.
- Chronic intoxication with ionic bromides, historically, has resulted from medical use of bromides but not from environmental or occupational exposure; depression, hallucinosis, and schizophreniform psychosis can be seen in the absence of other signs of intoxication. Bromides may also induce sedation, irritability, agitation, delirium, memory loss, confusion, disorientation, forgetfulness (aphasias), dysarthria, weakness, fatigue, vertigo, stupor, coma, decreased appetite, nausea and vomiting, diarrhoea, hallucinations, an acne like rash on the face, legs and trunk, known as bromochodema (seen in 25-30% of cases involving bromide ion), and a profuse discharge from the nostrils (coryza). Ataxia and generalised hyperreflexia have also been observed. Correlation of neurologic symptoms with blood levels of bromide is inexact. The use of substances such as brompheniramine, as antihistamines, largely reflect current day usage of bromides; ionic bromides have been largely withdrawn from therapeutic use due to their toxicity. Several cases of foetal abnormalities have been described in mothers who took large doses of bromides during pregnancy. Chronic exposure to cyanides and certain nitriles may result in interference to iodine uptake by thyroid gland and its consequent enlargement. This occurs following metabolic conversion of the cyanide moiety to thiocyanate.
Serotonin syndrome is generally associated with a favorable prognosis. Withdrawal may contribute to ongoing features. Following appropriate medical management, serotonin syndrome may persist for a number of days. Cases have reported muscle pain and weakness persisting for months although antidepressant withdrawal may contribute to ongoing features. Following appropriate medical management, serotonin syndrome is generally associated with a favorable prognosis.

### SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

Serotonin toxicity is more pronounced following supra-therapeutic doses and overdoses, and they merge in a continuum with the toxic effects of overdose. The serotonergic toxicity of SSRIs increases with dose, but even in over-dose it is insufficient to cause fatalities from serotonin syndrome in healthy adults. The syndrome occurs in approximately 14 to 16 percent of persons who overdose on SSRIs. It is usually only when drugs with different mechanisms of action are mixed together that elevations of central nervous system serotonin reach potentially fatal levels.

The symptoms are often described as a clinical triad of abnormalities:

- Cognitive effects: mental confusion, hypomania, hallucinations, agitation, headache, coma.
- Autonomic effects: shivering, sweating, fever, hypertension, tachycardia, nausea, diarrhea.
- Somatic effects: myoclonus/clonus (muscle twitching), hyperreflexia, tremor.

Symptom onset is usually rapid, often occurring within minutes after self-poisoning or a change in medication. Serotonin syndrome encompasses a wide range of clinical findings. Mild symptoms may only consist of tachycardia, shivering, diaphoresis (sweating), mydriasis (dilated pupils), myoclonus (intermittent tremor or twitching), as well as overactive or over-responsive reflexes. Moderate intoxication includes additional abnormalities such as hyperactive bowel sounds, hypertension and hyperthermia; a temperature as high as 40°C (104°F) is common in moderate intoxication. The overactive reflexes and clonus in moderate cases may be greater in the lower limbs than in the upper limbs. Mental status changes include hyper-vigilance and agitation. Severe symptoms often include severe hypertension and tachycardia that may lead to shock. Severe cases often have agitated delirium as well as muscular rigidity and high muscular tension. Temperature may rise to above 41.1°C (106.0°F) in life-threatening cases. Other abnormalities include metabolic acidosis, rhabdomyolysis, seizures, renal failure, and disseminated intravascular coagulation, these effects usually arise as a consequence of hyperthermia.

SSRIs appear to be safer in overdose when compared with traditional antidepressants such as the tricyclic antidepressants. This relative safety is supported both by case series and studies of deaths per numbers of prescriptions. However, case reports of SSRI poisoning have indicated that severe toxicity can occur and deaths have been reported following massive single ingestions, although this is exceedingly uncommon when compared to the tricyclic antidepressants.

Because of the wide therapeutic index of the SSRIs, most patients will have mild or no symptoms following moderate overdoses. The most commonly reported severe effect following SSRI overdose is serotonin syndrome; serotonin toxicity is usually associated with very high overdoses or multiple drug ingestion. Other reported significant effects include coma, seizures, and cardiac toxicity.

Treatment for SSRI overdose is mainly based on symptomatic and supportive care. Medical care may be required for agitation, maintenance of the airways, and treatment for serotonin syndrome. ECG monitoring is usually indicated to detect any cardiac abnormalities.

Supportive care includes:

- The control of agitation.
- The administration of serotonin antagonists (cyproheptadine or methysergide).
- The control of autonomic instability, and the control of hyperthermia.

The intensity of therapy depends on the severity of symptoms.

If the symptoms are mild, treatment may only consist of:

- Discontinuation of the offending medication or medications,
- Offering supportive measures,
- Giving benzodiazepines for myoclonus, and waiting for the symptoms to resolve.

Moderate cases should have:

- All thermal and cardiorespiratory abnormalities corrected and
- Can benefit from serotonin antagonists such as cyproheptadine.

Critically ill patients should receive the above therapies as well as:

- Sedation, neuromuscular paralysis, and
- Intubation with artificial ventilation.

Upon initiation of therapy and the discontinuation of serotonergic drugs most cases of serotonin syndrome resolve within 24 hours. Although delirium may persist for a number of days. Cases have reported muscle pain and weakness persisting for months although antidepressant withdrawal may contribute to ongoing features. Following appropriate medical management, serotonin syndrome is generally associated with a favorable prognosis.
**Vapour Pressure (mmHG):** Negligible
**Upper Explosive Limit (%):** Not available
**Specific Gravity (water=1):** Not available
**Lower Explosive Limit (%):** Not available

**EXTINGUISHING MEDIA**
- Water spray or fog.
- Foam.

**FIRE FIGHTING**
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear full body protective clothing with breathing apparatus.

When any large container (including road and rail tankers) is involved in a fire, consider evacuation by 800 metres in all directions.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen bromide, hydrogen fluoride, nitrogen oxides (NOx), other pyrolysis products typical of burning organic material.

May emit poisonous fumes.

**FIRE INCOMPATIBILITY**
- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**
- Glasses:
- Gloves:
- Respirator: Particulate

**Section 6 - ACCIDENTAL RELEASE MEASURES**

**MINOR SPILLS**
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

**MAJOR SPILLS**
- Clear area of personnel and move upwind.
- Alert Emergency Responders and tell them location and nature of hazard.

**Section 7 - HANDLING AND STORAGE**

**PROCEDURE FOR HANDLING**
- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

**RECOMMENDED STORAGE METHODS**
- Glass container.
- Lined metal can, Lined metal pail/drum
- Plastic pail.
- For low viscosity materials
- Drums and jerricans must be of the non-removable head type.
- Where a can is to be used as an inner package, the can must have a screwed enclosure.

**STORAGE REQUIREMENTS**
- Store in original containers.
- Keep containers securely sealed.

**Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION**
EXPOSURE CONTROLS
The following materials had no OELs on our records

- citalopram hydrobromide: CAS:59729-32-7

PERSONAL PROTECTION

RESPIRATOR
Particulate
Consult your EHS staff for recommendations

EYE
For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:

- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
dexterity
Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.
Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit.

ENGINEERING CONTROLS
Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES
Solid.
Mixes with water.
Contact with acids liberates very toxic gas.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided solid</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>360-361</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
</tr>
</tbody>
</table>
APPEARANCE
White crystalline powder; mixes with water.

Section 10 - CHEMICAL STABILITY

CONDITIONS CONTRIBUTING TO INSTABILITY
· Presence of incompatible materials.
· Product is considered stable.

STORAGE INCOMPATIBILITY
■ Avoid strong acids.
· Nitriles may polymerize in the presence of metals and some metal compounds.
· They are incompatible with acids; mixing nitriles with strong oxidizing acids can lead to extremely violent reactions.
· The covalent cyano group is endothermic and many organic nitriles are reactive under certain conditions; N-cyano derivatives are reactive or unstable.
· The majority of endothermic compounds are thermodynamically unstable and may decompose explosively under various circumstances of initiation.
· Many but not all endothermic compounds have been involved in decompositions, reactions and explosions and, in general, compounds with significantly positive values of standard heats of formation, may be considered suspect on stability grounds.
BRETERICK L.: Handbook of Reactive Chemical Hazards.
Avoid reaction with oxidizing agents.
For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION
citalopram hydrobromide

TOXICITY AND IRRITATION
CITALOPRAM HYDROBROMIDE:
■ No significant acute toxicological data identified in literature search.

CARCINOGEN
BROMINE COMPOUNDS (ORGANIC OR INORGANIC) | US Environmental Defense Scorecard Suspected Carcinogens | Reference(s) |
| | | P65-MC |

Section 12 - ECOLOGICAL INFORMATION

Very toxic to aquatic organisms.
This material and its container must be disposed of as hazardous waste.
Avoid release to the environment.
Refer to special instructions/ safety data sheets.

Section 13 - DISPOSAL CONSIDERATIONS

US EPA Waste Number & Descriptions
A. General Product Information
Reactivity characteristic: use EPA hazardous waste number D003 (waste code R).

Disposal Instructions
All waste must be handled in accordance with local, state and federal regulations.
| Puncture containers to prevent re-use and bury at an authorized landfill. Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate:
· Reduction
· Reuse
· Recycling
· Disposal (if all else fails) This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling
or reuse may not always be appropriate.
DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.
- Recycle wherever possible.
- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION

DOT:
Symbols: None
Hazard class or Division: 6.1
Identification Numbers: UN3249 PG: III
Label Codes: 6.1 Special provisions: T1, TP33
Packaging: Exceptions: 153
Packaging: Non-bulk: 213
Packaging: Quantity limitations: 5 kg
Passenger aircraft/rail:
Quantity Limitations: Cargo 5 kg Vessel stowage: Location: C
Aircraft only:
Vessel stowage: Other: 40
 Hazardous materials descriptions and proper shipping names:
Medicine, solid, toxic, n.o.s.

Air Transport IATA:
ICAO/IATA Class: 6.1 ICAO/IATA Subrisk: None
UN/ID Number: 3249 Packing Group: III
Special provisions: A3
Cargo Only
Packing Instructions: 200 kg Maximum Qty/Pack: 100 kg
Passenger and Cargo Passenger and Cargo
Packing Instructions: 677 Maximum Qty/Pack: 670
Passenger and Cargo Limited Quantity Passenger and Cargo Limited Quantity
Packing Instructions: 5 kg Maximum Qty/Pack: Y645
Shipping Name: MEDICINE, SOLID, TOXIC, N.O.S.(CONTAINS CITALOPRAM HYDROBROMIDE)

Maritime Transport IMDG:
IMDG Class: 6.1 IMDG Subrisk: None
UN Number: 3249 Packing Group: III
EMS Number: F-A, S-A Special provisions: 221 223
Limited Quantities: 5 kg Marine Pollutant: Yes
Shipping Name: MEDICINE, SOLID, TOXIC, N.O.S. (contains citalopram hydrobromide)

Section 15 - REGULATORY INFORMATION

No data for citalopram hydrobromide (CAS: 59729-32-7)

Section 16 - OTHER INFORMATION

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or
criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: May-26-2009
Print Date: Mar-22-2011